NCT05124080View on ClinicalTrials.gov

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2027

Conditions
Nail Psoriasis
Interventions
DRUG

Deucravacitinib

All participants will receive 6 mg of Deucravacitinib daily.

Trial Locations (1)

35233

University of Alabama at Birmingham - Department of Dermatology, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER